|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplemental Digital Content, Table 3.** **Neuromuscular Blockade Reversal Utilization and Monitoring** | | | | |
| Parameter | | Primary Survey | Secondary Survey | *P* |
| Reversal Agent(s) Used in Pediatric Practice | Sugam  Neostigmine  Both Sugam and Neostigmine  No Reversal Used | 106 (25.3%)  181 (43.2%)  111 (26.5%)  21 (5.0%) | 16 (21.3%)  30 (40.0%)  28 (37.3%)  1 (1.3%) | 0.19 |
| If Both Utilized, Frequency  Sugam Used | Mostly (50% - 100%)  Sometimes (25% - 50%)  Rarely (>0% - 25%) | 57 (51.4%)  46 (41.4%)  8 (7.2%) | 17 (56.7%)  11 (36.7%)  2 (6.7%) | 0.90 |
| Institutional Restriction on Reversal Agent(s) | Sugam Only  Neostigmine Only  Both  None | 19 (4.8%)  0 (0.0%)  47 (11.8%)  332 (83.4%) | 4 (5.3%)  0 (0.0%)  8 (10.7%)  63 (84.0%) | 0.93 |
| Voluntary Personal Restriction of Reversal Agent(s) Due to Cost or Efficacy | Sugam – Too Costly  Neostigmine – Too Costly  Sugam – Less Effective  Neostigmine – Less Effective  None | 99 (24.9%)\*  5 (1.3%)\*  13 (3.3%)\*  108 (27.1%)\*  199 (50.0%)\* | 14 (18.7%)  1 (1.3%)  2 (2.6%)  14 (18.7%)  44 (58.7%) | 0.41 |
| Patient Age Restrictions for Sugam Administration | No Age Restriction  <1 Month Old  <2 Months Old  <2 Years Old  <12 Years Old  12 Years Old to <18 Years Old | 243 (61.1%)\*  36 (9.0%)\*  37 (9.3%)\*  41 (10.3%)\*  21 (5.3%)\*  46 (11.6%)\* | 42 (56.0%)  7 (9.3%)  7 (9.3%)  6 (8.0%)  4 (5.3%)  9 (12.0%) | 0.99 |
| TOF Monitor Use Since Sugam Introduction | No Longer a Need  Still Routinely Use  Case-by-Case Basis  Never Monitored Before | 6 (1.7%)  231 (67.0%)  103 (29.9%)  5 (1.4%) | 0 (0.0%)  43 (57.3%)  31 (41.3%)  1 (1.3%) | 0.20 |

Data are presented as count (percentage). Analysis was performed with the Fisher exact test. P < 0.05 was considered statistically significant. Abbreviations: Sugam = Sugammadex, TOF = Train of Four.

\*Because multiple answers were accepted, percentages do not equal 100%.